ZyVersa Therapeutics and Larkspur Health Acquisition Corp. Announce Business Combination, Interim Financing and PIPE Investment Update
ZyVersa Therapeutics and Larkspur Health Acquisition Corp. announced a definitive business combination agreement on July 20, 2022, which is expected to be completed in Q4 2022. The aggregate committed financing for the business combination now totals $10.0 million, exceeding previous estimates. This includes approximately $8.5 million from a PIPE investment and $1.5 million from an interim financing round. Upon completion, Larkspur will be renamed ZyVersa Therapeutics, Inc. and listed under ticker ZVSA.
- Aggregate financing for the transaction is now $10.0 million.
- Combination expected to advance ZyVersa's clinical programs, including VAR 200 and IC 100.
- Risks associated with the transaction's completion, including shareholder approval.
- Potential regulatory hurdles and competition affecting product candidate approvals.
- Aggregate committed financing in support of the business combination now at
$10.0 million - ZyVersa and Larkspur entered into a definitive business combination agreement on July 20, 2022
- ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product candidates to address significant unmet medical needs in patients with renal and inflammatory diseases
- Transaction expected to be completed in fourth quarter of 2022
- Combined company expected to be named ZyVersa Therapeutics, Inc. and listed on NASDAQ under ticker "ZVSA"
BRIDGEWATER, N.J. and WESTON, Fla., Sept. 27, 2022 /PRNewswire/ -- ZyVersa Therapeutics, Inc. ("ZyVersa"), a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop product candidates that address unmet medical needs in the areas of renal and inflammatory diseases, and Larkspur Health Acquisition Corp. (NASDAQ: LSPR or "Larkspur"), a blank-check special purpose acquisition company, are pleased to announce that Larkspur has refiled with the U.S. Securities and Exchange Commission (the "SEC") their proxy/registration statement on Form S-4 (the "Registration Statement") in connection with the business combination agreement (the "Transaction") between Larkspur and ZyVersa previously announced on July 20, 2022. Larkspur and ZyVersa are also pleased to announce commitments of approximately
The PIPE Investment is anticipated to close simultaneously with the closing of the Transaction, which is expected to take place in the fourth quarter of 2022. Upon closing of the Transaction, Larkspur is expected to be renamed ZyVersa Therapeutics, Inc. and will continue to operate under the ZyVersa management team, led by Stephen C. Glover, Co-Founder, Chief Executive Officer, and Chairman of ZyVersa. The combined company's common stock is anticipated to be listed on NASDAQ under ticker symbol "ZVSA."
"We are grateful to our investors, including some who have been with us for many years, for their continued support and follow-on investments," said ZyVersa's CEO, Stephen C. Glover. "Their support will enable us to advance clinical evaluation of our cholesterol efflux mediator candidate (VAR 200) in patients with orphan renal disease, FSGS, and to progress our inflammasome ASC inhibitor candidate (IC 100) into Phase 1 trials. Patient targets for each of these product candidates have significant unmet medical needs that we believe our product candidates have potential to fulfill," continued Mr. Glover.
"We appreciate the vote of confidence from our new PIPE investors," stated Daniel J. O'Connor, Chairman and Chief Executive Officer of Larkspur. "Their support is a tribute to their belief in ZyVersa's CEO, Mr. Stephen Glover, who has successfully co-founded and led multiple biopharma companies; the extensive scientific and operational experience of ZyVersa's management team; and the potential of ZyVersa's proprietary drug candidates, VAR 200 and IC 100, to help drive improved health outcomes in patients with serious renal or inflammatory diseases," added Mr. O'Connor.
ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop product candidates that address unmet medical needs in the areas of renal and inflammatory diseases. ZyVersa's development pipeline includes phase 2a ready VAR 200, a cholesterol efflux mediator for treatment of rare kidney disease, focal segmental glomerulosclerosis. ZyVersa believes VAR 200 has the potential to treat other glomerular diseases, including Alport Syndrome and diabetic kidney disease. ZyVersa's development pipeline also includes IC 100, a novel inflammasome ASC inhibitor in development to treat a multitude of inflammatory diseases. For more information, please visit www.zyversa.com.
Larkspur is a Special Purpose Acquisition Company (SPAC) formed to identify a biopharmaceutical company that can develop and thrive as a newly formed public company and benefit from Larkspur's operational expertise and a significant infusion of capital. Each of Larkspur's management team and board of directors have been former management and executive leadership of private and public biopharmaceutical companies and have over 50+ years of aggregate investment and operational experiences. The team strongly believes in the growth opportunities in the biotechnology industry. They are experienced operators who seek to partner with top innovators and thinkers in the biopharmaceutical field. As operators, their entrepreneurial approach enables support for management teams in making impactful decisions with an eye toward growth and operational excellence. For more information, please visit www.lsprhealth.com.
In connection with the transactions described herein, Larkspur filed a registration statement on Form S-4 that includes a proxy statement with respect to the stockholder meeting of Larkspur and a prospectus with respect to securities of the combined company. After the registration statement is declared effective by the SEC, the proxy statement/prospectus will be sent to all Larkspur and ZyVersa stockholders. Larkspur will also file other documents regarding the proposed business combination with the SEC. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITIES HOLDERS OF LARKSPUR AND ZYVERSA ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED BUSINESS COMBINATION AS THEY BECOME AVAILABLE SINCE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED BUSINESS COMBINATION AND THE PARTIES TO THE PROPOSED BUSINESS COMBINATION.
Investors and securities holders will be able to obtain free copies of the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Larkspur through the website maintained by the SEC at https://sec.gov/. In addition, the documents filed by Larkspur may be obtained free of charge from Larkspur's website at www.lsprhealth.com or by written request to info@lsprhealth.com. Additional information about the proposed transaction, including a copy of the business combination agreement and investor presentation, will be provided in a Current Report on Form 8-K to be filed by Larkspur with the SEC which can be accessed at www.sec.gov as well as online at www.lsprhealth.com.
Larkspur, ZyVersa, and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from Larkspur's stockholders in connection with the proposed transaction. Information about Larkspur's directors and executive officers and their ownership of Larkspur's securities is set forth in Larkspur's Annual Report for the year ended December 31, 2021, which was filed with the SEC on Form 10-K, as modified or supplemented by any Form 3 or Form 4 filed with the SEC since the date of such filing. Other information regarding the interests of the participants in the proxy solicitation is included in the proxy statement/prospectus pertaining to the proposed Transactions that has been filed with the SEC. These documents can be obtained free of charge from the sources indicated above.
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such other jurisdiction.
This press release contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between Larkspur Health Acquisition Corp. ("Larkspur"), and ZyVersa Therapeutics, Inc. ("ZyVersa"). All statements other than statements of historical facts contained in this press release, including statements regarding Larkspur or ZyVersa's future results of operations and financial position, the amount of cash expected to be available to ZyVersa after the closing and giving effect to any redemptions by Larkspur's stockholders, ZyVersa's business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated product candidates, and expected use of proceeds, are forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to, the following risks relating to the proposed transaction: the occurrence of any event, change or other circumstances that could give rise to the termination of the Business Combination Agreement; the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of Larkspur's securities; the occurrence of any event, change or other circumstances that could give rise to the termination of the Business Combination Agreement; the inability to complete the Transactions, including due to failure to obtain approval of the shareholders of Larkspur or other conditions to closing in the Business Combination Agreement; the inability to obtain or maintain the listing of Larkspur's common stock on NASDAQ following the Transactions; the risk that the Transactions disrupt current plans and operations of ZyVersa as a result of the announcement and consummation of the Transactions; the ability to recognize the anticipated benefits of the Transactions, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that ZyVersa's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities; costs related to the Transactions; changes in applicable laws or regulations; the possibility that Larkspur or ZyVersa may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties to be identified in the proxy statement/prospectus (when available) relating to the Transactions, including those under "Risk Factors" therein, and in other filings with the SEC made by Larkspur. Moreover, ZyVersa operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Larkspur's and ZyVersa's control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law. Larkspur and ZyVersa assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither Larkspur nor ZyVersa gives any assurance that either Larkspur or ZyVersa or the combined company will achieve its expectations.
View original content to download multimedia:https://www.prnewswire.com/news-releases/zyversa-therapeutics-and-larkspur-health-acquisition-corp-announce-business-combination-interim-financing-and-pipe-investment-update-301634581.html
SOURCE ZyVersa Therapeutics, Inc.; Larkspur Health Acquisition Corp.
FAQ
What is the current financing status of Larkspur's business combination with ZyVersa?
When is the business combination between Larkspur and ZyVersa expected to close?
What will be the new name of Larkspur after the business combination?
What ticker symbol will the combined company trade under?
What are the main product candidates being developed by ZyVersa?
